Dr. Bolton is an assistant professor in the stem cell biology division at Washington University School of Medicine. She has a PhD in genetic epidemiology from Cambridge University. She attended medical school at UCLA School of Medicine. Her research focuses on translational computational genetics in oncology. Her research group uses genomics to define patient populations at high risk for development of malignancies through next generation and the development of molecularly-targeted prevention protocols..

During his early years at the Istituto Nazionale Tumori in Milan, Italy (1974-1980), Dr. Canetta’s focus was on clinical trials in lymphomas and gastrointestinal tumors, among others. Since joining Bristol-Myers Squibb (BMS) in 1980, Dr. Canetta has held numerous roles of increasing responsibility and leadership, including head of clinical cancer research; head of development, life cycle management; vice president, oncology global clinical research; and, finally, as vice president, global R&D oncology policy. His experience can be summarized with the introduction of 18 new BMS drugs to the general medical use (two outside of oncology) and the approval of over 50 regulatory dossiers for additional indications/formulations, including some outside of oncology. Dr. Canetta retired from BMS on August 14, 2015 and currently consults/cooperates with non-for-profit organizations, government agencies and professional societies.

Read More

During his early years at the Istituto Nazionale Tumori in Milan, Italy (1974-1980), Dr. Canetta’s focus was on clinical trials in lymphomas and gastrointestinal tumors, among others. Since joining Bristol-Myers Squibb (BMS) in 1980, Dr. Canetta has held numerous roles of increasing responsibility and leadership, including head of clinical cancer research; head of development, life cycle management; vice president, oncology global clinical research; and, finally, as vice president, global R&D oncology policy. His experience can be summarized with the introduction of 18 new BMS drugs to the general medical use (two outside of oncology) and the approval of over 50 regulatory dossiers for additional indications/formulations, including some outside of oncology. Dr. Canetta retired from BMS on August 14, 2015 and currently consults/cooperates with non-for-profit organizations, government agencies and professional societies.

Dr. Canetta’s area of expertise is cancer patient care, diagnosis and experimental treatment of hematologic malignancies and solid tumors, methodology of clinical trials, new drug development, and regulatory policy

Dr. Canetta holds an M.D. from Universita' degli Studi, in Milan, Italy. He also received State Certification from Istituto Nazionale Tumori and Board Certification from Universita' degli Studi in Milan, Italy.

Read Less

Roy Cosan is President of Renova Therapeutics. Prior to joining Renova, he was a Managing Director at Fjord Ventures. Roy’s experience includes 32 years with Johnson and Johnson. He was Vice President of New Product Development at Janssen Pharmaceuticals where he launched Risperdal and Reminyl.

Roy was also a Vice President with the Johnson & Johnson Development Corp., the venture capital arm of J&J where he invested in 19 companies and held 11 board of director seats. Roy helped build a virtual R&D capability within J&J Pharma.  He holds a B.B.A. with a concentration in marketing from Western Michigan University.

Jack has over 30 years of experience in the pharmaceutical industry, evenly split between R&D and licensing.

Jack was the Senior Vice President of Business Development for Arizona Technology Enterprises (AZTE), the technology transfer arm of Arizona State University, from 2007 to June of 2011. He now serves as a Senior Consultant to AZTE.  Jack has been a part of CPRIT for seven years, the last two serving as Chairman of the Product Development Review Council.

Jack served on the Board of Directors of Enzon Pharmaceuticals from 2008-2009 and is currently on the Board of Sophiris Bio.

Read More

Jack has over 30 years of experience in the pharmaceutical industry, evenly split between R&D and licensing.

Jack was the Senior Vice President of Business Development for Arizona Technology Enterprises (AZTE), the technology transfer arm of Arizona State University, from 2007 to June of 2011. He now serves as a Senior Consultant to AZTE.  Jack has been a part of CPRIT for seven years, the last two serving as Chairman of the Product Development Review Council.

Jack served on the Board of Directors of Enzon Pharmaceuticals from 2008-2009 and is currently on the Board of Sophiris Bio.

From 2002-2007, Jack was Vice President of External Science, Technology and Licensing at Bristol Myers Squibb. There, he was responsible for the acquisition and licensing of compounds, R&D technologies, and intellectual property to support the company's drug discovery and development efforts.  In this role, Jack and his team identified, evaluated, and coordinated due diligence activities on potential in- and out-licensing candidates in pre-clinical and clinical development across all therapeutic areas.  Jack's team consisted of 15 licensing professionals.

Prior to joining BMS, Jack was President and Chief Executive Officer of Message Pharmaceuticals, a privately held biotechnology company focused on the discovery of drugs active on RNA. Previously, he worked for SmithKline Beecham as Vice President, Scientific Licensing. He also held several other research and development roles of increasing responsibility with Johnson & Johnson, including Senior Director of Research for the Robert Wood Johnson Pharmaceutical Research Institute.  Jack began his career as a research scientist at E.I. DuPont.

Jack holds a B.S. in chemistry from Memphis State University and a Ph.D. in biochemistry from the California Institute of Technology. From there, he did postgraduate research in Dr. Richard Lerner's lab The Scripps Research Institute.

Read Less

Ginette is CEO of A&G Pharmaceutical, a company developing novel targets in Oncology which she co-founded in 2000 based on her discovery of the GP88/PGRN growth factor protein and her pioneering research demonstrating its importance in the tumorigenesis of many cancers.

Under her leadership, A&G has advanced several new therapeutic and diagnostic product candidates into preclinical and clinical development, including two breast cancer diagnostics.  In particular, a tissue test that measures GP88 in tumor biopsies as predictor of risk of recurrence in early stage breast cancer patients will be commercialized in Q3 2014.

Read More

Ginette is CEO of A&G Pharmaceutical, a company developing novel targets in Oncology which she co-founded in 2000 based on her discovery of the GP88/PGRN growth factor protein and her pioneering research demonstrating its importance in the tumorigenesis of many cancers.

Under her leadership, A&G has advanced several new therapeutic and diagnostic product candidates into preclinical and clinical development, including two breast cancer diagnostics.  In particular, a tissue test that measures GP88 in tumor biopsies as predictor of risk of recurrence in early stage breast cancer patients will be commercialized in Q3 2014.

With more than 25 years of in protein biochemistry and cell culture, Ginette is a recognized leader in the field of cancer biology research and development, with particular expertise in the characterization of novel targets involved in cell differentiation and tumorigenesis with a focus on cell adipocyte differentiation, and breast cancer. She is an Adjunct Professor at the University of Maryland School of Pharmacy and at the University of Maryland School of Medicine and a member of the Marlene and Stewart Greenebaum Cancer Center in Baltimore.

Prior to founding A&G, Ginette was a Professor at the University of Maryland School of Pharmacy and in the Program in Oncology at the University of Maryland Cancer Center. Before moving to Baltimore, she was Senior Scientist at the W. Alton Jones Cell Science Center in Lake Placid. She has published more than 80 papers, invited chapters, and reviews and is the inventor on 40 issued patents and more than 100 pending applications related to obesity and cancer molecular targets.

Ginette is Associate Editor of In Vitro Cell and Developmental Biology. She is the 2006 recipient of the Greater Baltimore Life Sciences Entrepreneurial Spirit Award and is a Scientific Advisory board member of the Maryland Industrial Partnerships Program and a Board Member of the Emerging Technology Center located in Baltimore. MD. Ginette received a PhD in Biochemistry from the University of Marseille and a DSc in Cell Biology from the University of Nice.

Read Less

David is currently responsible for developing  and executing integrated product development strategies for products ranging from discovery through market approval. David serves as an advisor to multidisciplinary program teams, contributing regulatory perspectives on clinical, preclinical, and chemistry, manufacturing and controls development decisions.

David has participated in the development of the regulatory strategy for programs involving central nervous system products, blood products, oncology therapeutics and vaccines, gene and stem cell products, immunomodulators, cardiovascular therapeutics, and metabolic and endocrine therapeutics.

Read More

David is currently responsible for developing  and executing integrated product development strategies for products ranging from discovery through market approval. David serves as an advisor to multidisciplinary program teams, contributing regulatory perspectives on clinical, preclinical, and chemistry, manufacturing and controls development decisions.

David has participated in the development of the regulatory strategy for programs involving central nervous system products, blood products, oncology therapeutics and vaccines, gene and stem cell products, immunomodulators, cardiovascular therapeutics, and metabolic and endocrine therapeutics.  He has experience in the preparation and filing of all types of regulatory submissions, from regulatory authority meeting briefing packages to INDs, IMPDs, CTAs, NDAs/BLAs and MAAs.  He has moderated dozens of regulatory authority meetings and negotiated the release of several products from regulatory clinical hold.

David’s primary areas of expertise include the design of preclinical and clinical study protocols and the integrated regulatory strategy for the development of novel drug and biological products; however, he is also well-versed in the development of products for 505(b)(2) and biosimilar marketing applications.

Read Less

Dr. Kristine Swiderek is Chief Scientific Officer at Mozart Therapeutics, a company that discovers and develops biologics to target a novel T cell network of pathogenic CD4 and cytolytic-regulatory CD8 T cells to establish immune balance in autoimmune and inflammatory disease.

Prior to joining Mozart Tx, Dr. Swiderek was Senior VP of Research at Alpine Immune Sciences and instrumental in building a pipeline and advancing protein-based immunotherapies for autoimmune disease and cancer. As Chief Scientific Officer at OncoResponse and Theraclone, she was responsible for leading the development of the I-STARTM antibody discovery platform yielding multiple clinical candidates.

She has over 25 years of research and leadership experience in the biopharmaceutical industry and a proven track record of forming successful R&D partnerships and of discovering and advancing a wide variety of protein therapeutic candidates into the clinic.

Read More

Dr. Kristine Swiderek is Chief Scientific Officer at Mozart Therapeutics, a company that discovers and develops biologics to target a novel T cell network of pathogenic CD4 and cytolytic-regulatory CD8 T cells to establish immune balance in autoimmune and inflammatory disease.

Prior to joining Mozart Tx, Dr. Swiderek was Senior VP of Research at Alpine Immune Sciences and instrumental in building a pipeline and advancing protein-based immunotherapies for autoimmune disease and cancer. As Chief Scientific Officer at OncoResponse and Theraclone, she was responsible for leading the development of the I-STARTM antibody discovery platform yielding multiple clinical candidates.

She has over 25 years of research and leadership experience in the biopharmaceutical industry and a proven track record of forming successful R&D partnerships and of discovering and advancing a wide variety of protein therapeutic candidates into the clinic.

Earlier in her career, Dr. Swiderek held several positions of increasing responsibility at ZymoGenetics, a public biotechnology company specializing in development of protein therapeutics where she successfully helped advance over a dozen therapeutic molecule candidates to be partnered, out-licensed and into clinical development. Prior to joining industry, Dr. Swiderek established a state-of-the-art analytical core facility at the City of Hope, National Cancer Center, where she collaborated with a group of prestigious scientists.

Dr. Swiderek received her Ph.D. in Protein Biochemistry from the Ruhr-Universität in Bochum, Germany. She completed her post- doctoral studies at City of Hope in Duarte, California and the Department of Biochemistry and Molecular Biology at Indiana University in Indianapolis, Indiana.

She has authored and co-authored over 60 peer reviewed articles and book chapters and has been a guest speaker at international scientific meetings and conventions.

Read Less

Colin Turnbull is a native of Edinburgh, Scotland. He obtained a Bachelor’s degree in Pharmacy from Heriot-Watt University, Edinburgh, and a Ph.D. in Organic Chemistry from Aston University, Birmingham, England, the subject of his Doctoral thesis being the synthesis and chemical characterization of novel anti-tumor triazenes. 

His career in the pharmaceutical industry spanned some 28 years during which he held increasingly senior positions in general management, Health Economics, and Clinical Research, culminating in his appointment as Vice President and Head of Global Oncology Clinical Research, Schering-Plough Research Institute (SPRI), and Chairman, Oncology Development Team, SPRI.

For the last 12 years, Dr. Turnbull has been an independent consultant specializing in carrying out due diligence assessment of oncology related investment opportunities for pharmaceutical and biotechnology industry clients and for venture capital firms.

Bo Saxberg is originally from Seattle, Washington, attending the University of Washington, where he received Summa Cum Laude Honors B.S. Mathematics and Honors B.S. Chemistry. At Cambridge University in England he received an Honours B.A./M.A. Cantab. in Physics, followed by an M.D. degree from Harvard and his Ph.D. in Physics from the Massachusetts Institute of Technology.

Read More

Bo Saxberg is originally from Seattle, Washington, attending the University of Washington, where he received Summa Cum Laude Honors B.S. Mathematics and Honors B.S. Chemistry. At Cambridge University in England he received an Honours B.A./M.A. Cantab. in Physics, followed by an M.D. degree from Harvard and his Ph.D. in Physics from the Massachusetts Institute of Technology.

Bo was a National Institutes of Health Fellow at MIT from 1989 to 1991, prior to joining Eli Lilly in Indianapolis as a Senior Research Scientist, continuing his prior research interests in QSAR/genomics/proteomics/physiomics. In 1993, he was named Director of Information Sciences at Eli Lilly. This group subsequently led a number of industry pioneering efforts at Lilly, including the first Internet home page for a pharmaceutical company, as well as developing interactive health economic models evolving to disease management, point of care prescribing, and the development of information resources to support modern product portfolio resource allocation decisions.

Joining Johnson & Johnson in 1995 as Vice President, Corporate Staff, Advanced Communications, he led Johnson & Johnson’s efforts in Medical Informatics, focusing on new business opportunities related to information technology in healthcare delivery and product development, ranging from defined contribution employee benefit models of health insurance, real-time auto-adjudication networks at the point of care supporting cost-quality decisions between doctor and patient, and a variety of technologies in health informatics including telemedicine, clinical studies and outcomes measurement, and electronic medical records.

In 2002, Bo left J&J to become founder and President of DDO Strategic Services, LLC, (“Design Development Optimization”). He is also founder and Manager of Oro Valley Ventures, LLC, investing in early stage companies. He is continuing his prior work in consulting, venture formation and business development with companies seeking to take leading advantage of change driven by new technologies and information access in health care, with application to product research & development, product and service marketing, financial services innovation, and clinical service innovation. Bo has also served as management/advisory board member for entrepreneurial companies, associations and venture firms, including Medidata, IntelliCyt, and Boston Millennia Partners, and is currently serving as management/advisory/review board member with iTel Companies, Science Media, the Cancer Prevention Research Institute of Texas, the EU IMI EHDEN Project, and the Friends of the National Library of Medicine.

Read Less

Steve brings over 25 years of experience as a CEO, entrepreneur, and venture capitalist investing across biotech, medical device, and digital health innovation.

As Managing Director of the Novartis Venture Fund for twelve years, he was actively engaged in all investment decisions across the $800M global portfolio, managed the medical device practice, and invested in biotech. Prior to Novartis, Steve was on the life science team at Prism Venture Partners, a $1.25B family of funds. He began his venture career as a Kauffman Fellow with Mid-Atlantic Venture Funds.

Steve is also an entrepreneur, having served as CEO of a Gregor Diagnostics (prostate cancer diagnostic), interim-CEO of ROX Medical (cardiovascular medical device) and COO of The Microbiome Health Research Institute. Early in his career, Steve was CEO of an industrial business he bought out of bankruptcy and built profitably over five years.

He consulted to Genentech Neuroscience Innovation related to best practices for corporate innovation, as well as evaluated novel approaches to treating neurological diseases including neuromuscular, precision psychiatry, and drug delivery.

He is Chairman of Spectrawave (Cardiovascular Imaging), Gregor Diagnostics and Celero Systems (intelligent drug delivery for opioid rescue). He is an advisor to the Rockefeller Neuroscience Institute, a member of the Virginia Venture Partners Investment Advisory Board, and served on the Innovation Advisory Board of Mass General Brigham Healthcare (2013-2018).

Steve holds an M.B.A. with distinction from the University of Michigan Business School and a B.S. in mechanical engineering from Columbia University.

Elaine V. Jones, Ph.D. has served as a member of the CytomX Therapeutics board of directors since December 2015. Dr. Jones served as Vice President, Worldwide Business Development and Senior Partner at Pfizer Ventures, where she was responsible for making and managing venture investments of strategic interest to Pfizer Inc., from December 2008 to April 2019.

Prior to joining Pfizer, Dr. Jones was a General Partner with EuclidSR Partners. She began her private equity career in 1999 at S.R. One, GlaxoSmithKline’s venture fund. Before that, she was Director of Scientific Licensing for SmithKline Beecham and a research scientist for SmithKline Beecham Pharmaceutical R&D. Dr. Jones currently serves on the board of directors for various privately held companies and also serves as a trustee of Juniata College. Dr. Jones previously served on the boards of directors of several publicly traded healthcare companies, including Mersana Therapeutics, Inc. from February 2015 to June 2018, Mirna Therapeutics, Inc. from December 2012 to June 2016, CytomX Therapeutics, Inc. from December 2014 to June 2016, Aquinox Pharmaceuticals, Inc. from June 2010 to February 2015 and Flexion Therapeutics, Inc. from December 2009 to June 2014.

Dr. Jones received a B.S. in biology from Juniata College and a Ph.D. in microbiology from the University of Pittsburgh.

James F. (Jim) Jordan is President and CEO of StraTactic, Inc., which enables both Fortune 500 and start-up companies to develop their go-to market, commercialization, and business development strategies. He is also a Distinguished Service Professor of Health Care and Biotechnology at Carnegie Mellon University’s Heinz College, where he has published numerous articles and books on innovation, start-ups, intellectual property, and health systems.

Jim is an active industry expert in healthcare and the life sciences. With a life-long passion for learning, Jim’s business accomplishments, combined with his academic achievements, enable him to apply his broad field of knowledge and experience to his clients. A dynamic communicator, Jim is an active author, speaker, and consultant.

Previously, Jim served as President and CEO of the Pittsburgh Life Sciences Greenhouse (PLSG), a public-private economic and venture fund owned by Carnegie Mellon University and the University of Pittsburgh. Jim was at the PLSG from 2005 to 2020 and applied his more than 25 years of experience to work with over 493 life science startup companies, with direct investment in 93 of them.

Prior to joining the PLSG, Mr. Jordan served as Senior Vice President of a $3 billion division of McKesson Corporation and as a Vice President for Marketing at Johnson & Johnson. He has leveraged this experience in several startup ventures and is active on several Boards of Directors. Mr. Jordan’s experience also includes consulting engagements with numerous companies such as Medtronic, Frost & Sullivan, Circuit City, Philip Morris, Northrop Grumman, Schwartz Pharmaceutical and Otsuka Pharmaceutical, among others.